Directed new share issue in Camurus AB (SE) — SEK 102 million

Carnegie acted as financial adviser and joint bookrunner in the directed new share issue of 1.1 million new shares at a subscription price of SEK 93 per share. Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. June 2018.